Quarterly ResultAug 5, 2026, 04:08 PM
Emergent Q2 Revenue +66% to $234.3M; $180.2M Net Loss on Impairment
AI Summary
Emergent BioSolutions reported Q2 2026 total revenues of $234.3 million, a 66% increase year-over-year, significantly exceeding guidance. However, the company posted a net loss of $180.2 million, largely due to a $191.3 million non-cash impairment charge related to its NARCAN® asset group. Adjusted net income and adjusted EBITDA showed strong improvements, rising 134% and 192% respectively. Concurrently, Emergent announced an organizational restructuring, including a reduction of approximately 90 roles, aiming for $40 million in annualized savings, and revised its full-year 2026 financial forecast downwards.
Key Highlights
- Q2 2026 Total Revenues increased 66% to $234.3 million.
- Q2 2026 Net Loss was $180.2 million, primarily due to a $191.3 million non-cash impairment charge on NARCAN® assets.
- Q2 2026 Adjusted Net Income improved 134% to $30.9 million.
- Q2 2026 Adjusted EBITDA increased 192% to $96.5 million, with a 41% margin.
- Organizational restructuring initiated, including a reduction of approximately 90 roles, expected to save $40 million annually.
- Naloxone product revenues decreased 22% to $52.4 million in Q2 2026, mainly due to lower OTC NARCAN® sales.
- MCM Products revenues increased 188% to $168.0 million in Q2 2026, driven by Smallpox MCM and Other Products.
- Full-year 2026 revenue forecast revised down to $645-$675 million from $720-$760 million.
Price Impact
More from EBS